---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-116764"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:54:54.682119+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology launches LYMPHIR, first commercial product, for CTCL

## Summary
- LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.
- Phase 3 pivotal study: 36.2% ORR, median time to response 1.4 months, no cumulative toxicity.
- Entering U.S. market estimated >$400M; permanent J-code J9161 and NCCN Category 2A inclusion.
- Ex-U.S. distribution pact with Integris Pharma for 12 Southern European/Balkan markets.
- Company holds exclusive rights to all markets except India, Japan, and parts of Asia.

## SEC filing metadata
- accession: 0001213900-25-116764
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/0001213900-25-116764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea0267560-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-116764
- JSON: https://secwatch.observer/filing/0001213900-25-116764.json
- Plain text: https://secwatch.observer/filing/0001213900-25-116764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.